IDiyas

For the Inventor, By the Inventor

North Wales, PA, United States of America

Gerhard J Sperl

USPTO Granted Patents = 24

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 239(Granted Patents)


Location History:

  • Stockton, CA (US) (1997 - 2002)
  • Horsham, PA (US) (1999 - 2002)
  • North Wales, PA (US) (2000 - 2003)

Company Filing History:

goldMedal22 out of 75 
 
Cell Pathways
 patents
silverMedal4 out of 972 
 
University of Arizona
 patents
bronzeMedal1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1997-2003

Loading Chart...
24 patents (USPTO):
1. 6610854 - Substituted condensation products of N-benzyl-3-indenylacentamides with heterocyclic aldehydes for neoplasia (2003-08-26),
2. 6486158 - [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia (2002-11-26),
3. 6455703 - 1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia (2002-09-24),
4. 6426349 - Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia (2002-07-30),
5. 6420410 - Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones (2002-07-16),
6. 6403831 - Substituted benzylidene indenyl formamides, acetamides and propionamides (2002-06-11),
7. 6348032 - Method of inhibiting neoplastic cells with benzimidazole derivatives (2002-02-19),
8. 6300346 - Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions (2001-10-09),
9. 6211177 - Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives (2001-04-03),
10. 6180629 - [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia (2001-01-30),
11. 6166053 - Substituted condensation products of N-benzyl-3-idenylacetamides with (2000-12-26),
12. 6160003 - 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment (2000-12-12),
13. 6121321 - Substituted methoxy benzylidene indenyl acetic and propionic acids for (2000-09-19),
14. 6071934 - Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating (2000-06-06),
15. 6066634 - Substituted condensation products of N-benzyl-3-indenylacetamides (2000-05-23),

Title: The Innovations of Gerhard J Sperl: A Pioneer in Neoplasia Treatment

Introduction:

Gerhard J Sperl, based in North Wales, Pennsylvania, is a distinguished inventor with a remarkable portfolio consisting of 24 patents. His work predominantly focuses on developing innovative compounds that hold promise in medical treatments, particularly in combating neoplasia.

Latest Patents:

Among his latest contributions to the field are two significant patents:

1. **Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia** - This patent describes compounds useful for inducing apoptosis and halting uncontrolled neoplastic cell proliferation, offering potential treatment options for various precancerous and cancerous conditions.

2. **[4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia** - This invention addresses the ongoing battle against neoplasia, providing a novel approach to treatment methodologies.

Career Highlights:

Gerhard has made significant strides in his career by working with notable organizations. He has contributed to the advancement of cancer treatment through his roles at Cell Pathways and the University of Arizona. Through his dedication and research, he has positioned himself as a leading inventor in the realm of medical innovation.

Collaborations:

Throughout his career, Gerhard has collaborated with esteemed colleagues such as Rifat Pamukcu and Gary A Piazza. Their combined expertise highlights a strong network of innovation and research aimed at tackling neoplastic diseases.

Conclusion:

Gerhard J Sperl exemplifies the spirit of innovation within the realm of medical science. His extensive work on patents targeting neoplasia showcases his commitment to advancing treatment options and improving patient outcomes. As he continues to build upon his impressive body of work, Sperl remains an influential figure in the field of medical inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…